Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 200   

Articles published

PFE 30.71 -0.21 (-0.68%)
price chart
Pfizer, Inc. (PFE) Declares $0.26 Quarterly Dividend; 3.4% Yield
Preliminary results from the Annual Meeting of Shareholders indicate that the company's 12 directors were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm ...
Pfizer Inc (NYSE:PFE) � Pfizer Hosts Annual Meeting of Shareholders Declares ...  Jutia Group
Related articles »  
Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D.
Pfizer, AstraZeneca Are Ripe for Pharma Deal: Real M&A  Bloomberg
Report: Pfizer approached AstraZeneca about purchase  The News Journal
Related articles »  
Pharma Drama: Pfizer Fails to Woo AstraZeneca; Valeant Pursues Allergan
It seems Pfizer Inc.'s (NYSE:PFE) attempts to woo AstraZeneca (NYSE:AZN) have failed, as AstraZeneca has rejected an offer from the world's largest pharmaceutical company, according to a report from The New York Times.
AstraZeneca reports profits fall as predators circle  CNBC.com
AstraZeneca Gains on Takeover Speculation as Profit Drops  Bloomberg
Related articles »  
4 Pharmaceuticals With Significant Potential
Indeed, since Pfizer lost its Lipitor patent, the company has moved quickly to streamline its business, spinning off its nutrition arm to Nestle and doing the same with its animal health department to Zoetis.
Related articles »  
Pfizer, Inc. (PFE) Reports Statistically Significant Data from Two OPT Program ...
Pfizer, Inc. (NYSE: PFE) announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an ...
Should Pfizer Attempt To Acquire AstraZeneca?
When done properly, the remaining shares (ie float) is reduced, leading to each share being entitled to a greater percentage of the company's earnings. The third method revolves around purchasing a competitor to grow revenues and market share. The ...
Related articles »  
AstraZeneca plc (ADR) (NYSE:AZN): Probability Of Second Approach By Pfizer ...
Dallas, Texas 04/22/2014 (ustradevoice) - AstraZeneca plc (ADR) (NYSE:AZN) rejected the huge deal of $101 billion that was offered by Pfizer Inc. (NYSE:PFE) as an attempt to takeover the British Drug Company. Pfizer is expected to try again for the ...
Company Update: Pfizer Inc (NYSE:PFE) � Pfizer Announces Positive Top-Line ...
Pfizer Inc (NYSE:PFE) [Business Wire] - Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials Program, OPT Pivotal #1 and OPT Pivotal #2 , evaluating the efficacy and safety of tofacitinib ...
Pfizer Treatment for Psoriasis Shows Positive Results in Studies  NASDAQ
Pfizer Reports Positive Phase 3 Results for Psoriasis Drug  Drug Discovery & Development
Related articles »  
Today's Market: Other Potential Buyout Targets For Pfizer
Discuss Pfizer and its need to do a deal. Talk potential names in the biotech space which would make attractive buyout candidates.
Related articles »  
Pfizer Inc. (NYSE:PFE): Potential New Oncology Therapy
Pfizer Inc. (NYSE:PFE) announced in early February some positive results from a randomized Phase 2 trial of palbociclib in combination with letrozole (for blocking the synthesis of estrogen) in post-menopausal women with estrogen receptor (ER) positive ...